10x Genomics, Inc.
MX ˙ BMV ˙ US88025U1097
SecurityMX:TXG / 10x Genomics, Inc.
InstitutionVestmark Advisory Solutions, Inc.
Latest Disclosed Ownership251,030 shares
Latest Disclosed Value $ 5,329,367
Vestmark Advisory Solutions, Inc. reports 7.26% decrease in ownership of TXG / 10x Genomics, Inc.

On May 15, 2026 - Vestmark Advisory Solutions, Inc. filed a 13F-HR form disclosing ownership of 251,030 shares of 10x Genomics, Inc. (MX:TXG) valued at $5,329,367 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 6, 2026 disclosing 270,668 shares of 10x Genomics, Inc.. This represents a change in shares of -7.26% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F 10X GENOMICS CL A COM 88025U109 251,030 -19,638 -7.26 5,329 20.73 0.0366
2026-02-06 2025-12-31 13F 10X GENOMICS CL A COM 88025U109 270,668 -3,772 -1.37 4,415 37.59 0.0596
2025-11-10 2025-09-30 13F 10X GENOMICS CL A COM 88025U109 274,440 -340,854 -55.40 3,208 -54.98 0.0612
2025-08-06 2025-06-30 13F 10X GENOMICS CL A COM 88025U109 615,294 321,894 109.71 7,125 178.21 0.1029
2025-05-13 2025-03-31 13F 10X GENOMICS CL A COM 88025U109 293,400 -2,139 -0.72 2,561 -48.98 0.0660
2025-02-06 2024-12-31 13F 10X GENOMICS CL A COM 88025U109 295,539 47,357 19.08 5,020 -10.41 0.1729
2024-11-14 2024-09-30 13F 10X GENOMICS CL A COM 88025U109 248,182 59,855 31.78 5,604 53.00 0.2086
2024-08-12 2024-06-30 13F 10X GENOMICS CL A COM 88025U109 188,327 32,284 20.69 3,663 -37.47 0.1529
2024-05-15 2024-03-31 13F 10X GENOMICS CL A COM 88025U109 156,043 78,634 101.58 5,856 35.21 0.2522
2024-02-06 2023-12-31 13F 10X GENOMICS CL A COM 88025U109 77,409 77,409 4,332 0.2201
2022-11-03 2022-09-30 13F 10X GENOMICS CL A COM 88025U109 0 -9,913 -100.00 0 -100.00
2022-08-04 2022-06-30 13F 10X GENOMICS CL A COM 88025U109 9,913 -753 -7.06 448 -44.76 0.0256
2022-04-27 2022-03-31 13F 10X GENOMICS CL A COM 88025U109 10,666 5,070 90.60 811 -2.64 0.0459
2022-01-31 2021-12-31 13F 10X GENOMICS CL A COM 88025U109 5,596 5,596 833 0.0470
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.